A combination of free and immunotherapy to create long-lived lung cancer
In the case of advanced non-small cell lung cancer, which drives the genetic negative, half of the patients experience different levels of progress after 6 to 9 months after the initial relief of the chemotherapy combination. This requires a combination of treatments and collaboration. The combination of immunotherapy (SBRT) is not only effective in controlling exposure to wild disease stoves, but at the same time SBRT can activate immunization, create synergies with immunotherapy, and even induce remote effects that increase the chances of long-term survival for late-stage patients. Typical case: The patient was diagnosed with right lung gland cancer with the right lung door in November 2019, with lymphoma knots and multiple intra-pulmonary transfer (T3N2M1, IV EGFR(-), ALK(-), ROS-1(-)). Progress soon followed by first-line chemotherapy in local hospitals, followed by the suspension of patients in second-line chemotherapy due to their inability to withstand the side-effects and the re-introduction of Chinese medicine. From February 2021 to February 2021, the CT of the chest (figure 1 left) was treated by a physiotherapy unit at the Shanghai City chest hospital. The lymphoma is seen in the right lung, both in isolation and in the right lung, moving forward. Taking into account that the patient has a large range of right lower-negative foliages and that the lower-pulmonary respiration is high, the treatment of the right lower-negative foliage SBRT began at 2021-3-8 with a total dose of 2400 cGy in three minutes. Joint PD-1 mono-immunotherapy treatment (2021-3-11 cases of PD-1 mono-anti-200 mg treatment every 3 weeks). A review in February after the treatment saw a marked improvement in the reduction of the right lung stove. At the same time, it was observed that the lymph no exposure and the lymph nodes of the right lung door had been reduced and improved (dissociation effect, figures 2 and 3, left, March 2021 and right, May 2021). 2022-7-19 review of the chest CT (Figure 1 right) warning stoves in the continuing decline, without visible manifestations of radioactive damage. Patients then receive PD-1 stand-alone maintenance treatment until 2022-8-31, after which they continue to receive regular follow-up visits. As of October 2024, the patient was still in a stable state, and the time of disease relief (DOR) had exceeded three and a half years. Figure 1 Left: Pre-treatment CT in February 2021 showed a pre-pregnosis; right: post-SBRT treatment in July 2022 CT showed a significant reduction. Figure 2 Left: CT hints before treatment in March 2021, transected lymph nodes; right: CT hints after treatment in May 2021 reduce lymph nodes before (not within the scope of SBRT) are remote effects. Figure 3 Left: CT hinted for right lung lymph nodes before treatment in March 2021; right: CT hinted for right lung lymph nodes earlier (not within SBRT) after treatment in May 2021 as a remote effect.
In the era of immunotherapy, which has driven the progress of non-small-cell lung cancers in the advanced stages of genetic negatives to systematic drug treatment, and in the context of back-line treatment options, in addition to the consideration of replacing systemic drugs, there is growing evidence that SBRT joint immunization can achieve the synergy of 1+1>2 by delaying the occurrence of immunotherapy resistance, improving the efficacy of treatment and extending the life of patients. In the case of late-stage lung cancer patients receiving first-line treatment, after an initial reduction in the previous system, it is possible to have longer disease control periods, or even longer survival periods, if they receive early local treatment of the remaining stoves, to strengthen the efficacy of the treatment, and to increase the tumour resistance of their own bodies through a combination of therapeutic-immunotherapy treatments, and to allow the immune system to identify and attack tumour cells more effectively.
Lung cancer
